JP2008510835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008510835A5 JP2008510835A5 JP2007530177A JP2007530177A JP2008510835A5 JP 2008510835 A5 JP2008510835 A5 JP 2008510835A5 JP 2007530177 A JP2007530177 A JP 2007530177A JP 2007530177 A JP2007530177 A JP 2007530177A JP 2008510835 A5 JP2008510835 A5 JP 2008510835A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- lower alkyl
- obese
- hours
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 31
- 238000009472 formulation Methods 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 17
- 229940079593 drugs Drugs 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 238000002360 preparation method Methods 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 229920000642 polymer Polymers 0.000 claims 10
- 229920001577 copolymer Polymers 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims 7
- 206010033307 Overweight Diseases 0.000 claims 7
- 235000020825 overweight Nutrition 0.000 claims 7
- 208000008589 Obesity Diseases 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 230000001629 suppression Effects 0.000 claims 6
- 230000002422 KATP channel opening Effects 0.000 claims 5
- FCTRVTQZOUKUIV-MCDZGGTQSA-M potassium;[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound [K+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)([O-])=O)[C@@H](O)[C@H]1O FCTRVTQZOUKUIV-MCDZGGTQSA-M 0.000 claims 5
- 230000004580 weight loss Effects 0.000 claims 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
- 206010012601 Diabetes mellitus Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 239000008103 glucose Substances 0.000 claims 4
- 230000001965 increased Effects 0.000 claims 4
- 230000003914 insulin secretion Effects 0.000 claims 4
- 206010006550 Bulimia nervosa Diseases 0.000 claims 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 3
- 125000004429 atoms Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000011248 coating agent Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 238000005265 energy consumption Methods 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical group 0.000 claims 3
- 239000011859 microparticle Substances 0.000 claims 3
- 238000007254 oxidation reaction Methods 0.000 claims 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 3
- 230000002459 sustained Effects 0.000 claims 3
- 201000010874 syndrome Diseases 0.000 claims 3
- 229940107161 Cholesterol Drugs 0.000 claims 2
- 206010058108 Dyslipidaemia Diseases 0.000 claims 2
- 206010061227 Lipid metabolism disease Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 2
- 230000001430 anti-depressive Effects 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 claims 2
- 230000003111 delayed Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 235000020828 fasting Nutrition 0.000 claims 2
- 230000002496 gastric Effects 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 239000003456 ion exchange resin Substances 0.000 claims 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 230000003204 osmotic Effects 0.000 claims 2
- 230000003647 oxidation Effects 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- GDLBFKVLRPITMI-UHFFFAOYSA-N (+-)-Isoprenaline Chemical group ClC1=CC=C2NC(C)=NS(=O)(=O)C2=C1 GDLBFKVLRPITMI-UHFFFAOYSA-N 0.000 claims 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- 206010068783 Alstroem syndrome Diseases 0.000 claims 1
- 201000005932 Alstrom syndrome Diseases 0.000 claims 1
- 201000001321 Bardet-Biedl syndrome Diseases 0.000 claims 1
- 208000008020 Cohen syndrome Diseases 0.000 claims 1
- 206010014476 Elevated cholesterol Diseases 0.000 claims 1
- 206010015037 Epilepsy Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 208000009576 Hypercholesterolemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010056715 Laurence-Moon-Bardet-Biedl syndrome Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N Orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N Rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 claims 1
- 229960003015 Rimonabant Drugs 0.000 claims 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N Sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 230000003110 anti-inflammatory Effects 0.000 claims 1
- 230000000561 anti-psychotic Effects 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 239000002830 appetite depressant Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000004059 degradation Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 239000003405 delayed action preparation Substances 0.000 claims 1
- 229960004042 diazoxide Drugs 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000000302 ischemic Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229960001243 orlistat Drugs 0.000 claims 1
- 238000010951 particle size reduction Methods 0.000 claims 1
- 230000001575 pathological Effects 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 229960004425 sibutramine Drugs 0.000 claims 1
- 231100000486 side effect Toxicity 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000007962 solid dispersion Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 230000002522 swelling Effects 0.000 claims 1
- 239000003451 thiazide diuretic agent Substances 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Claims (33)
- 式II,式III,式IV又は式V:
R 1 は、水素,低級アルキル,置換型低級アルキル、シクロアルキル、及び置換型シクロアルキルから成る群より選択され;
R 2a は、水素、及び低級アルキルから成る群より選択され;
R 2b は、水素、及び低級アルキルから成る群より選択され;
Xは、1、2又は3原子鎖であり、ここで、各原子は、炭素、硫黄及び窒素から互いに独立して選択され、及び各原子は、ハロゲン、ヒドロキシル、低級アルキル、置換型低級アルキル、低級アルコキシ、シクロアルキル、置換型シクロアルキル、置換型低級アルコキシ、アミノ、及び置換型アミノによって任意に置換されていてもよく;及び
環Bは、飽和環、一不飽和環、多数不飽和環、又は芳香環であり、及び
式IV及びVにおいて:
R 1 は、水素、低級アルキル、置換型低級アルキル、シクロアルキル、及び置換型シクロアルキルから成る群より選択され;
R 2a は、水素、低級アルキル、及び置換型低級アルキルから成る群より選択され;
R 2b iは、水素、低級アルキル、及び置換型低級アルキルから成る群より選択され;
R 3 は、水素、ハロゲン、低級アルキル、置換型低級アルキル、アミノ、及び置換型アミノから成る群より選択され;
R 4 は、水素、ハロゲン、低級アルキル、置換型低級アルキル、アミノ、及び置換型アミノから成る群より選択される]
のK ATP チャンネル開放因子の放出制御製剤であって、
ここで、前記放出制御製剤は経口投与に適したものであることを特徴とする製剤。 - 経口投与用に製剤される請求項1に記載の製剤。
- KATPチャンネル開放因子を10から100mg含むことを特徴とする単回投与用の請求項1又は2に記載の製剤。
- KATPチャンネル開放因子を100から200mg含むことを特徴とする単回投与用の請求項1又は2に記載の製剤。
- KATPチャンネル開放因子を200から300mg含むことを特徴とする単回投与用の請求項1又は2に記載の製剤。
- KATPチャンネル開放因子を300から500mg含むことを特徴とする単回投与用の請求項1又は2に記載の製剤。
- KATPチャンネル開放因子を500から2000mg含むことを特徴とする単回投与用の請求項1又は2に記載の製剤。
- KATPチャンネル開放因子はジアゾキシドであることを特徴とする請求項1から7のいずれか1項に記載の製剤。
- (a)粉砕、噴霧乾燥、又はその他の微細化技術を含む粒子径低減、
(b)イオン交換樹脂の使用、
(c)内包複合体の使用、
(d)低粘度ヒプロメルロース、低粘度メチルセルロース、又は同様に機能する賦形剤、又はそれらの混合物を含む可溶化剤による式II、III、IV又はVの化合物の小型化、
(e)製剤前に、式II、III、IV又はVの化合物を塩と連結すること、
(f)式II、III、IV又はVの化合物の固体分散の使用、
(g)自己乳化システムの使用、
(h)製剤に対する1種又はそれ以上の界面活性剤の添加、又は、
(i)ナノ粒子の使用、
の内の少なくとも一つによって得られることを特徴とする請求項1から8のいずれか1項に記載の製剤。 - 胃内移行が終わるまで、KATPチャンネル開放因子の前記製剤からの放出を実質的に抑制する、少なくとも一つの成分を含むことを特徴とする請求項2に記載の製剤。
- 成分が:(a)錠剤の上に加圧コーティングとして適用されるpH感受性ポリマー又はコポリマー、(b)錠剤の上に薄層として適用されるpH感受性ポリマー又はコポリマー、(c)カプセルシステムに対して薄層として適用されるpH感受性ポリマー又はコポリマー、(d)カプセル包摂微粒子に適用されるpH感受性ポリマー又はコポリマー、(e)錠剤の上に加圧コーティングとして適用される非水性可溶ポリマー又はコポリマー、(f)錠剤の上に薄層として適用される非水性可溶ポリマー又はコポリマー、(g)カプセルシステムに対して薄層として適用される非水性可溶ポリマー又はコポリマー、(h)微粒子に適用される非水性可溶ポリマー又はコポリマー、(i)浸透圧ポンプシステム、(j)イオン交換樹脂によって調節されるシステム、及び(k)これらの組み合わせから成る群より選択され、pH感受性ポリマー又はコポリマーが、酸性条件下での分解に対して耐性を持つことを特徴とする請求項10に記載の製剤。
- 投与後、2−4時間の期間に渡るKATPチャンネル開放因子の持続放出に寄与する成分を更に含むことを特徴とする請求項1から7のいずれか1項に記載の製剤。
- 投与後、4−8時間の期間に渡るKATPチャンネル開放因子の持続放出に寄与する成分を更に含むことを特徴とする請求項1から7のいずれか1項に記載の製剤。
- 投与後、8−24時間の期間に渡るKATPチャンネル開放因子の持続放出に寄与する成分を更に含むことを特徴とする請求項1から7のいずれか1項に記載の製剤。
- 成分が:(a)pH感受性ポリマーコーティング、(b)ヒドロゲル、(c)被覆基質からの薬剤の拡散速度を調節するフィルムコーティング、(d)薬剤の放出速度を調節する侵食性基質、(e)更にカプセル化され、又は錠剤に圧縮されることができる薬剤のポリマー被覆ペレット、顆粒又は微粒子、(f)薬剤を含む浸透圧ポンプシステム、(g)薬剤の加圧コート錠剤、又は(h)上記の成分の組み合わせ、であることを特徴とする請求項12から14のいずれか1項に記載の製剤。
- 別の製薬学的活性剤を更に含むことを特徴とする請求項1から7のいずれか1項に記載の製剤。
- 別の製薬学的活性剤が、肥満、糖尿病前駆状態、糖尿病、高血圧、鬱病、コレステロール上昇、むくみ、その他の肥満関連付随病態、虚血性及び再環流損傷、又は癲癇、分裂病、躁病、又はその他の精神病態から成る群より選択される病態の治療に有用であることを特徴とする請求項16に記載の製剤。
- 肥満、体重過剰、又は肥満傾向の個人に対する投与が:(a)絶食時インスリン分泌の抑制、(b)グルコース刺激時インスリン分泌の抑制、(c)エネルギー消費の上昇、(d)脂肪のベータ酸化の上昇、又は、(e)約24時間の過食症の抑制、の内の少なくとも一つをもたらすことを特徴とする請求項1から7のいずれか1項に記載の製剤。
- 肥満、体重過剰、又は肥満傾向の個人に対する投与が:(a)絶食時インスリン分泌の抑制、(b)グルコース刺激時インスリン分泌の抑制、(c)エネルギー消費の上昇、(d)脂肪のベータ酸化の上昇、又は、(e)約18時間の過食症の抑制、の内の少なくとも一つをもたらすことを特徴とする請求項1から7のいずれか1項に記載の製剤。
- 肥満又は体重過剰の被験体において減量を誘発又は維持するか、又は肥満傾向の被験体において減量を維持するための医薬組成物において、24時間当たり2回以下投与するのに適合するよう製剤された請求項1又は2に記載の製剤を含むことを特徴とする医薬組成物。
- 製剤は24時間当たり1回投与するのに適合するよう製剤されている、請求項20記載の医薬製剤。
- 肥満又は体重過剰の被験体において減量を誘発するための医薬組成物において、請求項1又は2に記載の医薬製剤の連日用量を含み、K ATP 処方の連日用量は50と180mgの間にあることを特徴とする組成物。
- 肥満、体重過剰、又は肥満傾向の個人において肥満関連付随病態を治療するための医薬組成物において、24時間当たり2回以下投与するよう製剤されている請求項1又は2に記載の製剤の治療的有効量を含む組成物。
- 肥満の個人において減量を実現するための医薬組成物において、24時間当たり2回以下投与するよう製剤されている請求項1又は2に記載の製剤の治療的有効量を含む組成物。
- 体重過剰、肥満、又は肥満傾向の個人においてエネルギー消費又は脂肪のベータ酸化を上昇させる方法において、24時間当たり2回以下投与するよう製剤されている請求項1又は2に記載の製剤の治療的有効量を含む組成物。
- 糖尿病前駆病態の個人の、糖尿病への移行を阻止するための医薬組成物において、24時間当たり2回以下投与するよう製剤されている請求項1又は2に記載の製剤の治療的有効量を含む組成物。
- 糖尿病又は糖尿病前駆状態の個人に対し正常なグルコース耐性を回復するための医薬組成物において、請求項1又は2に記載の製剤の治療的有効量を含む組成物。
- 糖尿病の進行を遅らせる、又は阻止するための医薬組成物において、24時間当たり2回以下投与するよう製剤されている請求項1又は2に記載の製剤の治療的有効量を含む組成物。
- 前記製剤が、24時間当たり1回投与するよう製剤されている請求項23−26及び28のいずれかに記載の組成物。
- 肥満、又は肥満関連付随病態、又は、K ATP チャンネルを含む他の疾患又は病態を治療するための医薬組成物において、請求項1又は2に記載の製剤、及びシブトラミン、オルリスタット、リモナバント、非チアジド利尿剤、コレステロールを下げる薬、HDLコレステロールを上げる薬、LDL結合コレステロールを下げる薬、血圧を下げる薬、抗鬱作用を持つ薬、インスリン感度を改善する薬、グルコース利用又は取り込みを改善する薬、抗癲癇作用を持つ薬、抗炎症作用を持つ薬、食欲抑制作用を持つ薬、循環トリグリセリドを下げる薬、及び、体重過剰又は肥満の個人において減量を誘発するために使われる薬から成る群より選択される薬剤を含む医薬組成物。
- K ATP チャンネル開放因子、及びK ATP チャンネル開放因子の投与による副作用の発生率を減少させるための医薬製剤を含む、疾病又は疾患を治療するための医薬組成物であって、前記医薬製剤は胃通過が完了するまで、K ATP チャンネル開放因子のリリースを遅らせることを特徴とする組成物。
-
抗精神病薬を用いる治療対象における体重増加、異常脂質血症又は耐糖能異常を予防又は治療するための遅延放出医薬組成物において、K ATP チャンネル開放因子を含む組成物。 - 肥満、過食症、異常脂質血症、又は(a)プラダー・ウィリー症候群(Prader Willi Syndrome)、(b)フレーリッヒ症候群(Froelich’s syndrome)、(c)コーエン症候群(Cohen syndrome)、(d)サミット症候群(Summit syndrome)、(e)アルストレム症候群(Alstrom Syndrome)、(f)ベルジェセン症候群(Borjesen Syndrome)、(g)バルデー・ビードル症候群(Bardet−Biedl Syndrome)、又は(h)抗リポタンパク血症I、II、III、IV型を含むエネルギー消費の低下によって特徴付けられる疾患を治療するための遅延放出医薬組成物において、K ATP チャンネル開放因子を含む組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60408504P | 2004-08-25 | 2004-08-25 | |
US62421904P | 2004-11-03 | 2004-11-03 | |
US65457105P | 2005-02-22 | 2005-02-22 | |
US66891205P | 2005-04-06 | 2005-04-06 | |
PCT/US2005/030481 WO2006026469A2 (en) | 2004-08-25 | 2005-08-25 | Pharmaceutical formulations of potassium atp channel openers and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008510835A JP2008510835A (ja) | 2008-04-10 |
JP2008510835A5 true JP2008510835A5 (ja) | 2011-04-28 |
Family
ID=36000625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007530177A Pending JP2008510835A (ja) | 2004-08-25 | 2005-08-25 | カリウムatpチャンネル開放因子の製剤処方、及びその使用 |
Country Status (12)
Country | Link |
---|---|
US (6) | US20060051418A1 (ja) |
EP (3) | EP2208496A1 (ja) |
JP (1) | JP2008510835A (ja) |
CN (1) | CN104958270A (ja) |
AT (1) | ATE463249T1 (ja) |
AU (2) | AU2005280058B2 (ja) |
CA (1) | CA2578224A1 (ja) |
DE (1) | DE602005020462D1 (ja) |
DK (1) | DK1781265T3 (ja) |
ES (2) | ES2342090T3 (ja) |
HK (2) | HK1161133A1 (ja) |
WO (1) | WO2006026469A2 (ja) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004096201A1 (en) | 2003-04-29 | 2004-11-11 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
JP2008510835A (ja) * | 2004-08-25 | 2008-04-10 | エッセンシャリス,インク. | カリウムatpチャンネル開放因子の製剤処方、及びその使用 |
WO2006088875A2 (en) * | 2005-02-14 | 2006-08-24 | Albert Einstein College Of Medicine Of Yeshiva University | Intranasal administration of modulators of hypothalamic atp-sensitive potassium channels |
US9757384B2 (en) | 2005-04-06 | 2017-09-12 | Essentialis, Inc. | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome |
US20060243696A1 (en) * | 2005-04-27 | 2006-11-02 | Spada Lon T | Tip design for reducing capillary leakage and water loss for plastic container closures |
EP2135603B1 (en) | 2005-11-22 | 2013-01-02 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
US20070161661A1 (en) * | 2005-12-28 | 2007-07-12 | Mellican Sean M | Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanesulfonate |
PL1968601T3 (pl) | 2006-01-05 | 2012-03-30 | Essentialis Inc | Sole związków otwierających kanały potasowe ATP i ich zastosowanie |
WO2007132344A2 (en) * | 2006-05-09 | 2007-11-22 | Aurobindo Pharma Limited | Controlled release compositions of an antidepressant agent |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
KR20180066272A (ko) | 2006-11-09 | 2018-06-18 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
AU2008272923A1 (en) * | 2007-07-02 | 2009-01-08 | Essentialis, Inc. | Salts of potassium ATP channel openers and uses thereof |
MX2010012909A (es) | 2008-05-30 | 2011-02-25 | Orexigen Therapeutics Inc | Metodos para tratamiento de condiciones de grasa visceral. |
EP3187182B1 (en) | 2008-09-02 | 2021-03-03 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
EP2395987A1 (en) | 2009-02-12 | 2011-12-21 | Coöperatieve Mirzorg U.A., Arnhem | Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders |
BRPI1011876B1 (pt) | 2009-04-29 | 2020-03-31 | Amarin Pharma, Inc. | Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular |
EP2424521A4 (en) | 2009-04-29 | 2015-03-04 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE |
DK2443246T3 (en) | 2009-06-15 | 2018-03-26 | Amarin Pharmaceuticals Ie Ltd | COMPOSITIONS AND METHODS FOR REDUCING TRIGLYCERIDES WITHOUT INCREASING LDL-C LEVELS IN AN INDIVIDUAL WITH CURRENT STATE THERAPY |
RU2012116079A (ru) | 2009-09-23 | 2013-10-27 | АМАРИН КОРПОРЕЙШН ПиЭлСи | Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения |
RU2616496C2 (ru) | 2010-01-11 | 2017-04-17 | Ориксиджен Терапьютикс, Инк. | Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты) |
EP2422787A1 (en) * | 2010-08-17 | 2012-02-29 | Neurotec Pharma, S.L. | Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als) |
AU2011305462B2 (en) | 2010-09-23 | 2015-11-26 | Abbvie Bahamas Ltd. | Monohydrate of an azaadamantane derivative |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
EP2819675A4 (en) | 2012-02-27 | 2015-07-22 | Essentialis Inc | SALTS OF KALIUM ATP CHANNEL OPENERS AND USES THEREOF |
WO2013184837A1 (en) | 2012-06-06 | 2013-12-12 | Orexigen Therapeutics, Inc. | Methods of treating overweight and obesity |
EP4342546A3 (en) | 2012-06-29 | 2024-05-22 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US20140221358A1 (en) * | 2013-02-06 | 2014-08-07 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
WO2014197753A1 (en) * | 2013-06-08 | 2014-12-11 | Sedogen, Llc | Method of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
EP3099304A4 (en) | 2014-01-31 | 2018-01-10 | Mayo Foundation for Medical Education and Research | Novel therapeutics for the treatment of glaucoma |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
PL3217963T3 (pl) * | 2014-11-14 | 2020-10-19 | Essentialis, Inc. | Sposoby leczenia osobników z zespołem pradera-williego lub smith-magenis |
WO2016157053A1 (en) * | 2015-03-31 | 2016-10-06 | Kolinpharma S.P.A. | A composition for the treatment of neuropathies and/or neuropathic pain |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
KR20210110890A (ko) | 2018-09-24 | 2021-09-09 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
WO2021239106A1 (zh) * | 2020-05-28 | 2021-12-02 | 杭州起岸生物科技有限公司 | 钾atp通道调节剂在制备抗糖尿病肾病药物中的应用 |
WO2022076746A1 (en) * | 2020-10-09 | 2022-04-14 | Scienture, Inc. | Losartan liquid formulations and methods of use |
WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
WO2024086252A1 (en) * | 2022-10-18 | 2024-04-25 | Rhythm Pharmaceuticals, Inc. | Novel atp-sensitive potassium channel potentiators, their preparation and use |
CN116236451B (zh) * | 2023-04-18 | 2024-04-19 | 淄博市中心医院 | 一种阿卡波糖片、制备方法及用途 |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3269906A (en) * | 1966-08-30 | Imino-j,x-dihydro-l,z,x-benzothiadiazine- i,i-dioxides | ||
US2678311A (en) * | 1952-05-07 | 1954-05-11 | Delmar Chem | Theophylline salts |
US2986573A (en) | 1961-01-18 | 1961-05-30 | Schering Corp | Method for the treatment of hypertension |
GB982072A (en) | 1960-09-19 | 1965-02-03 | Scherico Ltd | Benzothiadiazine-1,1-dioxides and processes for their manufacture |
US3304228A (en) * | 1961-06-26 | 1967-02-14 | Schering Corp | Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides |
US3265573A (en) * | 1962-07-27 | 1966-08-09 | Squibb & Sons Inc | Benzothiadiazinesulfonamide-1, 1-dioxide composition |
US3345365A (en) * | 1964-03-31 | 1967-10-03 | Schering Corp | Novel 1, 2, 4-benzothiadiazine-1, 1-dioxide derivatives |
US3431138A (en) * | 1967-07-14 | 1969-03-04 | American Cyanamid Co | Method for coating pharmaceutical forms with methyl cellulose |
JPS5248889B2 (ja) | 1973-10-29 | 1977-12-13 | ||
CA1056827A (en) * | 1974-10-29 | 1979-06-19 | Haruki Nishimura | 1,2,4-benzothiadiazine 1,1-dioxide derivatives |
US4184039A (en) * | 1977-12-01 | 1980-01-15 | Paul Finkelstein | Benzothiadiazine 1, 1-dioxides |
DE2757925A1 (de) | 1977-12-24 | 1979-06-28 | Bayer Ag | Diazacyclo-1.2.4-benzothiadizine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
JPS5995212A (ja) | 1982-11-23 | 1984-06-01 | Nitto Electric Ind Co Ltd | 基剤組成物及び外用医薬組成物 |
DE3530857A1 (de) * | 1985-08-29 | 1987-03-05 | Hoechst Ag | Verfahren zur herstellung von niedrigviskosen celluloseethern |
GB8601204D0 (en) | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
GB2186485B (en) * | 1986-02-13 | 1988-09-07 | Ethical Pharma Ltd | Slow release formulation |
ATE110954T1 (de) | 1988-01-29 | 1994-09-15 | Peter H Proctor | Haarwachstumanregung mit nitroxyd und anderen radikalen. |
US5063208A (en) * | 1989-07-26 | 1991-11-05 | Abbott Laboratories | Peptidyl aminodiol renin inhibitors |
US6361795B1 (en) | 1989-09-05 | 2002-03-26 | Alza Corporation | Method for lowering blood glucose |
US5284845A (en) | 1991-03-14 | 1994-02-08 | Paulsen Elsa P | Use of oral diazoxide for the treatment of disorders in glucose metabolism |
US5252338A (en) * | 1991-06-27 | 1993-10-12 | Alza Corporation | Therapy delayed |
FR2690160A1 (fr) | 1992-04-15 | 1993-10-22 | Rhone Poulenc Rorer Sa | Application de dérivés d'acide 2H-1,2,4-benzothiadiazine-1,1-dioxyde-3-carboxylique à la préparation de médicaments, les produits nouveaux, leur préparation et les médicaments les contenant. |
US5378704A (en) * | 1992-04-15 | 1995-01-03 | E. R. Squibb & Sons, Inc. | Non-peptidic angiotensin-II-receptor-antagonists |
US5356775A (en) * | 1992-07-29 | 1994-10-18 | Brigham & Women's Hospital | Primary structure for functional expression from complementary DNA of a mammalian ATP-sensitive potassium channel |
US5629045A (en) * | 1992-09-17 | 1997-05-13 | Richard L. Veech | Biodegradable nosiogenic agents for control of non-vertebrate pests |
US5376384A (en) * | 1992-12-23 | 1994-12-27 | Kinaform Technology, Inc. | Delayed, sustained-release pharmaceutical preparation |
FR2703051B1 (fr) | 1993-03-26 | 1995-04-28 | Adir | Nouvelles pyridothiadiazines, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent. |
US5747278A (en) * | 1993-05-21 | 1998-05-05 | California Institute Of Technology | DNA encoding inward rectifier, G-protein activated, mammalian, potassium KGA channel and uses thereof |
US5965620A (en) * | 1993-07-23 | 1999-10-12 | Vide Pharmaceuticals | Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure |
WO1995015352A1 (en) * | 1993-12-01 | 1995-06-08 | Universite Du Quebec A Montreal | Albumin based hydrogel |
AU1839695A (en) * | 1994-02-08 | 1995-08-29 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | Dna encoding atp-sensitive potassium channel proteins and uses thereof |
US5399359A (en) | 1994-03-04 | 1995-03-21 | Edward Mendell Co., Inc. | Controlled release oxybutynin formulations |
FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
DE69632569T2 (de) * | 1995-06-09 | 2005-08-18 | Euroceltique S.A. | Formulierungen und verfahren für eine verlängerte lokalanästhesie |
US6225310B1 (en) * | 1996-01-17 | 2001-05-01 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
US6309855B1 (en) * | 1996-02-08 | 2001-10-30 | Centre National De La Recherche (Cnrs) | Family of mammalian potassium channels, their cloning and their use, especially for the screening of drugs |
US5885980A (en) * | 1996-06-25 | 1999-03-23 | Enrique G. Gutierrez | Composition and method for treating diabetes |
AU4133997A (en) | 1996-09-12 | 1998-04-02 | Yarom Cohen | Pharmaceutical composition for the treatment of syndrome x of reaven |
AU744156B2 (en) * | 1996-10-28 | 2002-02-14 | General Mills Inc. | Embedding and encapsulation of controlled release particles |
GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
CA2309597A1 (en) * | 1997-11-10 | 1999-05-20 | Hiroshi Sorimachi | Sustainedly releasing agents for medicines and sustainedly released medicinal compositions containing the same |
WO2000004879A1 (en) * | 1998-07-24 | 2000-02-03 | Andrix Pharmaceuticals, Inc. | Granule modulating hydrogel system |
GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6197976B1 (en) * | 1998-12-14 | 2001-03-06 | Syntex (U.S.A.) Llc | Preparation of ketorolac |
US6329367B1 (en) * | 1998-12-18 | 2001-12-11 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
JP2002533411A (ja) * | 1998-12-23 | 2002-10-08 | ジー.ディー.サール エルエルシー | 心臓血管に適用するための組み合わせ |
CH693625A5 (it) | 1999-02-18 | 2003-11-28 | Inpharma Sa | Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi. |
US20020119933A1 (en) * | 2000-07-28 | 2002-08-29 | Butler Terri L. | Compositions and methods for improving cardiovascular function |
US6197765B1 (en) * | 1999-06-08 | 2001-03-06 | Pnina Vardi | Use of diazoxide for the treatment of metabolic syndrome and diabetes complications |
US20030220329A1 (en) * | 1999-09-17 | 2003-11-27 | Duke University | Method of improving beta-adrenergic receptor function |
US6436944B1 (en) | 1999-09-30 | 2002-08-20 | Pfizer Inc. | Combination effective for the treatment of impotence |
DE60032915T2 (de) * | 1999-10-04 | 2007-10-25 | Bernstein, Lawrence Richard, Dr., Menlo Park | Gallium komplexe von 3-hydroxy-4-pyronen zur behandlung von durch intrazelluläre prokaryoten, dns- und retro-viren verursachten infektionen |
AU1338801A (en) * | 1999-10-22 | 2001-05-08 | Wake Forest University | Methods of protecting neuronal function |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
FR2801587B1 (fr) * | 1999-11-30 | 2002-01-11 | Adir | Nouveaux derives de benzothiadiazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US20020192302A1 (en) * | 1999-12-16 | 2002-12-19 | Tsung-Min Hsu | Transdermal and topical administration of antidepressant drugs using basic enhancers |
DE10012199A1 (de) * | 2000-03-13 | 2001-09-20 | Haarmann & Reimer Gmbh | Eingekapselte Substanzen mit kontrollierter Freisetzung |
GB2361185A (en) * | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
US6635277B2 (en) * | 2000-04-12 | 2003-10-21 | Wockhardt Limited | Composition for pulsatile delivery of diltiazem and process of manufacture |
AU2001265840A1 (en) * | 2000-06-26 | 2002-01-08 | Novo-Nordisk A/S | Use of potassium channel agonists for reducing fat food comsumption |
ATE320318T1 (de) * | 2000-06-30 | 2006-04-15 | Ngimat Co | Verfahren zur abscheidung von materialien |
US7271182B2 (en) | 2000-08-04 | 2007-09-18 | Takeda Pharmaceutical Company Limited | Salts of benzimidazole compound and use thereof |
WO2002030400A1 (fr) * | 2000-10-06 | 2002-04-18 | Takeda Chemical Industries, Ltd. | Preparations solides |
AU2002213174A1 (en) * | 2000-10-13 | 2002-04-22 | Massaharu Akao | Treatment of apoptotic cell death |
GB0025473D0 (en) * | 2000-10-17 | 2000-11-29 | Pfizer Ltd | Pharmaceutical combinations |
JP2004517100A (ja) * | 2000-12-20 | 2004-06-10 | グラクソ グループ リミテッド | hPPARアルファアゴニストとしての置換オキサゾールおよびチアゾール |
EP1345947A1 (en) | 2000-12-21 | 2003-09-24 | Novo Nordisk A/S | A new process for preparing fused 1,2,4-thiadiazine derivatives |
US7560473B2 (en) * | 2001-01-19 | 2009-07-14 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences, P.L.A. | Amine derivative with potassium channel regulatory function, its preparation and use |
TW478039B (en) | 2001-04-09 | 2002-03-01 | Promos Technologies Inc | Phase shift alignment system |
US20020173636A1 (en) * | 2001-04-13 | 2002-11-21 | Millennium Pharmaceuticals, Inc. | 66784, a novel human potassium channel and uses therefor |
US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
CA2414912A1 (en) * | 2001-12-20 | 2003-06-20 | University Of Saskatchewan Technologies Inc. | Pleurotus extract and use in treating hypertension |
DE10209979A1 (de) * | 2002-03-07 | 2003-09-25 | Ratiopharm Gmbh | Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung |
DE60330764D1 (de) * | 2002-04-26 | 2010-02-11 | Hoffmann La Roche | Pharmazeutische zusammensetzung enthaltend einen lipase - inhibitor und glucomannan |
US6960346B2 (en) * | 2002-05-09 | 2005-11-01 | University Of Tennessee Research Foundation | Vehicles for delivery of biologically active substances |
WO2003099801A1 (en) | 2002-05-24 | 2003-12-04 | Smithkline Beecham Corporation | Novel anti-infectives |
AU2003237992B2 (en) | 2002-06-10 | 2009-02-19 | Metabolex, Inc. | Methods and compositions for treating and diagnosing diabetes |
WO2003105896A1 (en) | 2002-06-14 | 2003-12-24 | Novo Nordisk A/S | Combined use of a modulator of cd3 and a beta cell resting compound |
US20040132826A1 (en) * | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
US7902203B2 (en) * | 2002-11-01 | 2011-03-08 | Abbott Laboratories, Inc. | Anti-infective agents |
US20050075331A1 (en) * | 2003-10-06 | 2005-04-07 | Pratt John K. | Anti-infective agents |
US20040097492A1 (en) * | 2002-11-01 | 2004-05-20 | Pratt John K | Anti-infective agents |
AU2003287640A1 (en) * | 2002-11-12 | 2004-06-03 | Collegium Pharmaceutical, Inc. | Inertial drug delivery system |
US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
US7311727B2 (en) * | 2003-02-05 | 2007-12-25 | Board Of Trustees Of The University Of Arkansas | Encased stent |
CL2004000366A1 (es) * | 2003-02-26 | 2005-01-07 | Pharmacia Corp Sa Organizada B | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. |
US20040204472A1 (en) | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
US20040229803A1 (en) * | 2003-04-22 | 2004-11-18 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders |
FR2854634B1 (fr) | 2003-05-05 | 2005-07-08 | Servier Lab | Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP4220314B2 (ja) | 2003-06-12 | 2009-02-04 | 株式会社テクノ菱和 | 装着型軟x線検出器 |
US7378414B2 (en) * | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
US20050089473A1 (en) * | 2003-09-10 | 2005-04-28 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
AU2005256675A1 (en) * | 2004-06-23 | 2006-01-05 | Neurotec Pharma, S.L. | Compounds for the treatment of inflammation of the central nervous system |
CN101849921A (zh) * | 2004-08-13 | 2010-10-06 | 贝林格尔·英格海姆国际有限公司 | 包含普拉克索或其可药用盐的延长释放片剂 |
JP2008510835A (ja) | 2004-08-25 | 2008-04-10 | エッセンシャリス,インク. | カリウムatpチャンネル開放因子の製剤処方、及びその使用 |
MX2007004889A (es) * | 2004-10-25 | 2007-09-11 | Solvay Pharm Gmbh | Composiciones farmaceuticas que comprenden antagonistas del receptor cannabinoide cb1 y activadores de canales de potasio para el tratamiento de la diabetes mellitus tipo i, la obesidad y trastornos relacionados. |
FR2877338B1 (fr) * | 2004-11-03 | 2007-01-26 | Servier Lab | Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US20060263805A1 (en) * | 2005-03-16 | 2006-11-23 | Andre Terzic | Diagnosing and treating potassium channel defects |
US9757384B2 (en) | 2005-04-06 | 2017-09-12 | Essentialis, Inc. | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome |
PL1968601T3 (pl) | 2006-01-05 | 2012-03-30 | Essentialis Inc | Sole związków otwierających kanały potasowe ATP i ich zastosowanie |
JP2007294934A (ja) * | 2006-03-30 | 2007-11-08 | Canon Inc | 計測方法及び装置、露光装置及び方法、調整方法、並びに、デバイス製造方法 |
US20070254863A1 (en) * | 2006-04-27 | 2007-11-01 | Jochen Antel | Use of CBx cannabinoid receptor modulators as potassium channel modulators |
AU2008272923A1 (en) | 2007-07-02 | 2009-01-08 | Essentialis, Inc. | Salts of potassium ATP channel openers and uses thereof |
US20120238554A1 (en) | 2007-07-02 | 2012-09-20 | Cowen Neil M | Salts of potassium atp channel openers and uses thereof |
EP2819675A4 (en) | 2012-02-27 | 2015-07-22 | Essentialis Inc | SALTS OF KALIUM ATP CHANNEL OPENERS AND USES THEREOF |
PL3217963T3 (pl) | 2014-11-14 | 2020-10-19 | Essentialis, Inc. | Sposoby leczenia osobników z zespołem pradera-williego lub smith-magenis |
-
2005
- 2005-08-25 JP JP2007530177A patent/JP2008510835A/ja active Pending
- 2005-08-25 EP EP10159141A patent/EP2208496A1/en not_active Withdrawn
- 2005-08-25 DE DE602005020462T patent/DE602005020462D1/de active Active
- 2005-08-25 AT AT05791600T patent/ATE463249T1/de not_active IP Right Cessation
- 2005-08-25 AU AU2005280058A patent/AU2005280058B2/en active Active
- 2005-08-25 DK DK05791600.9T patent/DK1781265T3/da active
- 2005-08-25 ES ES05791600T patent/ES2342090T3/es active Active
- 2005-08-25 EP EP20110184285 patent/EP2404605B1/en active Active
- 2005-08-25 ES ES11184285.2T patent/ES2539969T3/es active Active
- 2005-08-25 WO PCT/US2005/030481 patent/WO2006026469A2/en active Application Filing
- 2005-08-25 EP EP05791600A patent/EP1781265B1/en active Active
- 2005-08-25 CA CA002578224A patent/CA2578224A1/en not_active Abandoned
- 2005-08-25 US US11/212,130 patent/US20060051418A1/en not_active Abandoned
- 2005-08-25 CN CN201510404296.8A patent/CN104958270A/zh active Pending
-
2009
- 2009-02-09 US US12/368,215 patent/US20090149451A1/en not_active Abandoned
- 2009-02-12 US US12/370,456 patent/US20090148525A1/en not_active Abandoned
-
2010
- 2010-11-30 AU AU2010246520A patent/AU2010246520B2/en active Active
-
2012
- 2012-02-28 HK HK12101988.8A patent/HK1161133A1/xx unknown
-
2014
- 2014-08-12 US US14/458,032 patent/US9782416B2/en active Active
-
2016
- 2016-03-14 HK HK16102894.5A patent/HK1214945A1/zh unknown
-
2018
- 2018-03-27 US US15/937,594 patent/US20180280405A1/en not_active Abandoned
-
2019
- 2019-11-22 US US16/692,852 patent/US20200237772A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008510835A5 (ja) | ||
RU2340358C2 (ru) | Композиция, ингибирующая секрецию кислоты в желудке | |
RU2314810C2 (ru) | Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена | |
ES2539969T3 (es) | Formulaciones farmacéuticas de activadores del canal de potasio de ATP y usos de las mismas | |
JP2955524B2 (ja) | 固体薬剤調製物 | |
CN112770726A (zh) | 大麻素的缓释配方 | |
TWI522100B (zh) | 含有納布啡(nalbuphine)之藥學組成物及其用途 | |
JP2002516270A (ja) | リポ酸の制御放出 | |
US20110268808A1 (en) | Dual-release pharmaceutical suspension | |
EP0385846A1 (fr) | Composition pharmaceutique à libération prolongée d'acide valproîque | |
KR20100099731A (ko) | 레보도파 방출 제어형 제제 및 이의 용도 | |
JP2008500288A (ja) | 経口治療用化合物の供給系 | |
KR101156054B1 (ko) | 안정한 에페리손 함유 서방성 의약조성물 | |
BR112015026418B1 (pt) | Formulação de liberação prolongada de colchicina e uso da referida formulação de liberação prolongada de colchicina | |
JP2005508865A (ja) | アポモルフィン、6aR−(−)−N−プロピル−ノルアポモルフィンおよびそれらの誘導体、並びにそれらのプロドラッグを効率的に投与するための薬学的処方剤 | |
KR20140052966A (ko) | 다중미립자 l-멘톨 제제 및 관련 방법 | |
CN116712432A (zh) | 氘代多潘立酮组合物、方法和制备物 | |
JP2019524727A (ja) | 朝の無動状態を治療するための拍動性薬物送達系 | |
BR112020008128A2 (pt) | comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos | |
JP2009537455A (ja) | プロトンポンプインヒビターに基づく経口薬 | |
JP2007509146A (ja) | レボドーパの持続効果のための組成物及び投与形 | |
TWI344840B (en) | Modafinil modified release pharmaceutical compositions | |
US20220370450A1 (en) | Controlled-release composition for oral administration comprising complex of alpha adrenergic blocker compound and clay mineral | |
WO2014171542A1 (ja) | 放出制御製剤 | |
CN114786647A (zh) | 口服药学立即释放组合物和用于重量减轻的治疗方法 |